Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy followed by thoracic radiotherapy and apatinib for extensive-stage small cell lung cancer
ChiCTR2300075166Phase 2Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Aug 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, Rivoceranib, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoints: Progression-free survival and Survival rates at 1 year and 2 years. Started Aug 2023; status: recruiting.
02
Drugs
adebrelimabRivoceranibcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300075166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075166.